ArticleCirculation2017
Long Noncoding RNA Facilitated Gene Therapy Reduces Atherosclerosis in a Murine Model of Familial Hypercholesterolemia.
Open access · bronzeAbstract readLetter
In one paragraph
Article in Circulation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 11% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- Targeting epigenetics and non-coding RNAs in atherosclerosis: from mechanisms to therapeutics.Pharmacology & therapeutics · 2019Pooled it
- Non-coding RNAs in lipid metabolism and their roles in atherosclerosis.Nature reviews. Cardiology · 2026Review
- A cholesterol-responsive hepatic tRNA-derived small RNA regulates cholesterol homeostasis and atherosclerosis development.Nature communications · 2025Article
- Gene Therapy Approaches for Atherosclerosis Focusing on Targeting Lipid Metabolism and Inflammation.International journal of molecular sciences · 2025Review
- Long noncoding RNAs in familial hypercholesterolemia: biomarkers, therapeutics, and AI in precision medicine.Lipids in health and disease · 2025Review
- Comprehensive insights and In silico analysis into the emerging role of LincRNAs in lung diseases pathogenesis; a step toward ncRNA precision.Functional & integrative genomics · 2025Review
- TFEB SUMOylation in macrophages accelerates atherosclerosis by promoting the formation of foam cells through inhibiting lysosomal activity.Cellular and molecular life sciences : CMLS · 2023Article
- Rare variants in long non-coding RNAs are associated with blood lipid levels in the TOPMed whole-genome sequencing study.American journal of human genetics · 2023Article
- Long Non-Coding RNAs as Emerging Targets in Lung Cancer.Cancers · 2023Review
- Hypothalamic long noncoding RNA AK044061 is involved in the development of dietary obesity in mice.International journal of obesity (2005) · 2021Article
- Role of long non-coding RNAs in adipogenesis: State of the art and implications in obesity and obesity-associated diseases.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2021Review
- Decoding LncRNAs.Cancers · 2021Review
- Regulation of Long Non-Coding RNAs by Statins in Atherosclerosis.Biomolecules · 2021Review
- Our emerging understanding of the roles of long non-coding RNAs in normal liver function, disease, and malignancy.JHEP reports : innovation in hepatology · 2021Review
- Gene Therapy for Cardiovascular Disease: Basic Research and Clinical Prospects.Frontiers in cardiovascular medicine · 2021Review
- Comprehensive Analysis of Differentially Expressed lncRNA, circRNA and mRNA and Their ceRNA Networks in Mice With Severe Acute Pancreatitis.Frontiers in genetics · 2021Article
- Emerging Role of Long Non-Coding RNAs in Diabetic Vascular Complications.Frontiers in endocrinology · 2021Review
- LncRNAs as Therapeutic Targets and Potential Biomarkers for Lipid-Related Diseases.Frontiers in pharmacology · 2021Review
- Article
- Long Noncoding RNAs in Atherosclerosis and Vascular Injury: Pathobiology, Biomarkers, and Targets for Therapy.Arteriosclerosis, thrombosis, and vascular biology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Peter TontonozFrom Department of Pathology and Laboratory Medicine, Howard Hughes Medical Institute (P.T., M.J., D.S.), Department of Medicine, Division of Cardiology (X.W., Z.Z., D.S., T.S.), University of California, Los Angeles.
Xiaohui WuFrom Department of Pathology and Laboratory Medicine, Howard Hughes Medical Institute (P.T., M.J., D.S.), Department of Medicine, Division of Cardiology (X.W., Z.Z., D.S., T.S.), University of California, Los Angeles.
Marius JonesFrom Department of Pathology and Laboratory Medicine, Howard Hughes Medical Institute (P.T., M.J., D.S.), Department of Medicine, Division of Cardiology (X.W., Z.Z., D.S., T.S.), University of California, Los Angeles.
Zhengyi ZhangFrom Department of Pathology and Laboratory Medicine, Howard Hughes Medical Institute (P.T., M.J., D.S.), Department of Medicine, Division of Cardiology (X.W., Z.Z., D.S., T.S.), University of California, Los Angeles.
David SalisburyFrom Department of Pathology and Laboratory Medicine, Howard Hughes Medical Institute (P.T., M.J., D.S.), Department of Medicine, Division of Cardiology (X.W., Z.Z., D.S., T.S.), University of California, Los Angeles.
Tamer SallamFrom Department of Pathology and Laboratory Medicine, Howard Hughes Medical Institute (P.T., M.J., D.S.), Department of Medicine, Division of Cardiology (X.W., Z.Z., D.S., T.S.), University of California, Los Angeles. tsallam@mednet.ucla.edu.
Howard Hughes Medical Institute · US
Funding
TRAININGU54GM114833 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LINDSEY, MERRY L., PING, PEIPEI · 2014 to 2017
$13.8MNUCLEAR RECEPTOR SIGNALING PATHWAYS IN ATHEROGENESISR01HL066088 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI TONTONOZ, PETER J · 2001 to 2018
$5.4MRNA-binding proteins in atherosclerosisR01HL139549 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Tamer Sallam · 2018 to 2026
$3.3MLong Non-coding RNAs in Cardiometabolic DiseaseK08HL128822 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SALLAM, TAMER · 2015 to 2019
$884kNHLBI NIH HHS K08 HL128822NHLBI NIH HHS R01 HL066088NHLBI NIH HHS R01 HL139549NIGMS NIH HHS U54 GM114833
Abstract
PubMed holds no abstract for this paper.
Indexed as
AnimalsAortaAortic DiseasesAtherosclerosisCholesterolDependovirusDisease Models, AnimalGene Expression RegulationGenetic TherapyGenetic VectorsHyperlipoproteinemia Type IILiverLiver X ReceptorsMice, KnockoutPlaque, AtheroscleroticReceptors, LDLCholesterolLiver X ReceptorsReceptors, LDLRNA, Long NoncodingTriglyceridesatherosclerosischolesterolgenetic therapyRNA, long noncoding
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.